Precision Medicine and PET/Computed Tomography: Challenges and Implementation

Rathan M Subramaniam1

  • 1Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Department of Clinical Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Advanced Imaging Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA.

PET Clinics
|November 20, 2016
PubMed

Insights

Precision medicine matches therapies to patients using molecular targets. Positron Emission Tomography/computed tomography (PET/CT) addresses challenges in precision oncology, improving patient selection and therapy assessment.

Area of Science:

  • Oncology
  • Medical Imaging
  • Precision Medicine

Background:

  • Precision medicine aims to tailor treatments to individual patients based on molecular profiles, lifestyle, and environment.
  • Key challenges in implementing precision oncology include identifying predictive biomarkers, understanding tumor heterogeneity, and assessing therapy response early.
  • Resistance to therapies and treatment failures remain significant hurdles in oncology.

Purpose of the Study:

  • To explore the role of PET/computed tomography (PET/CT) in overcoming challenges in precision medicine.
  • To highlight how PET/CT can facilitate the implementation of precision diagnostics and personalized cancer therapies.
  • To demonstrate PET/CT's utility in addressing tumor heterogeneity and early therapy assessment.

Main Methods:

  • Review of current literature on precision medicine and PET/CT applications in oncology.
  • Analysis of how PET/CT addresses biomarker discovery and patient selection.
  • Evaluation of PET/CT's capability in mapping tumor heterogeneity and monitoring treatment response.

Main Results:

  • PET/CT aids in identifying patients who will benefit from specific targeted therapies.
  • The technology assists in visualizing and understanding tumor heterogeneity, a factor in treatment failure.
  • PET/CT enables early assessment of therapy effectiveness and detection of treatment resistance.

Conclusions:

  • PET/computed tomography (PET/CT) is a valuable tool for advancing precision medicine in oncology.
  • PET/CT facilitates crucial aspects of precision oncology, including patient stratification and early treatment evaluation.
  • Integrating PET/CT can significantly improve the delivery and success of personalized cancer treatments.